Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$38.70 USD
-0.29 (-0.74%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $38.73 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.70 USD
-0.29 (-0.74%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $38.73 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
by Zacks Equity Research
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -253.66% and -62.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirum Pharmaceuticals (MIRM) in Focus: Stock Moves 5.9% Higher
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.